Medicines Development and Regulation
From molecule to label
Regulatory questions reward a clean map of the development timeline. Preclinical work (pharmacology, toxicology, GLP safety studies) supports an IND in the US or a CTA in the EU, which permits human dosing. Phase I emphasizes safety, tolerability and pharmacokinetics, usually in small numbers of healthy volunteers, though oncology and some biologics use patients. Phase II explores dose-ranging and preliminary efficacy. Phase III confirms efficacy and safety in the population intended for the label and provides pivotal evidence for an NDA, BLA or MAA. Phase IV and post-marketing commitments address long-term safety, rare events and real-world use.
Learn the expedited pathways and what each actually grants. Orphan designation offers incentives for rare diseases. Fast track provides frequent regulatory interaction and rolling review. Breakthrough therapy designation adds intensive guidance based on preliminary clinical evidence of substantial improvement. Priority review shortens the review clock, not the evidence standard. Accelerated approval permits a surrogate endpoint with confirmatory trials required. Risk management tools - REMS in the US, risk management plans in the EU - sit alongside post-approval pharmacovigilance obligations.
Trap: assuming an expedited pathway lowers the evidentiary bar. It changes timing and interaction, not the requirement to demonstrate benefit.
Rule of thumb: match the question's verb to the phase - "characterize" and "tolerability" point to Phase I; "confirm" and "pivotal" point to Phase III. Worked example: a compound for a rare disease with no available therapy may receive orphan designation and accelerated approval on a surrogate endpoint, but approval is conditional on a post-marketing trial verifying clinical benefit, and failure to conduct it can lead to withdrawal.